Literature DB >> 12671522

Mirtazapine-induced serotonin syndrome.

Eroboghene E Ubogu1, Bashar Katirji.   

Abstract

An 85-year-old woman developed sudden confusion and dysarthria progressing to mutism, orobuccal dyskinesias, generalized tremors worse with activity, ataxia, and rigidity with cog wheeling without high-grade fevers or dysautonomia. These findings were related temporally to the institution of mirtazapine as monotherapy for a major depressive illness with superimposed anxiety disorder. Withdrawal of the agent resulted in early notable clinical resolution with only residual hypertonia after 2 weeks. This is a rare report of serotonin syndrome induced by mirtazapine monotherapy. The hypothesized pathophysiologic mechanism in this case is overstimulation of serotonin (5-hydroxytryptamine or 5-HT) type 1A receptors (5-HT(1A)) in the brainstem and spinal cord in an individual with risk factors for hyperserotoninemia resulting from reduced, acquired endogenous serotonin metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671522     DOI: 10.1097/00002826-200303000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  3 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Risk of Serotonin Syndrome with Isoniazid.

Authors:  Michael E O'Brien; Ronak G Gandhi; Camille N Kotton; Meagan L Adamsick
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

3.  Mirtazapine overdose is unlikely to cause major toxicity.

Authors:  I Berling; G K Isbister
Journal:  Clin Toxicol (Phila)       Date:  2013-11-14       Impact factor: 4.467

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.